UNITY Biotechnology ROE 2017-2025 | UNBX
Current and historical return on equity (ROE) values for UNITY Biotechnology (UNBX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| UNITY Biotechnology ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2025-03-31 |
$-0.03B |
$0.00B |
-260.00% |
| 2024-12-31 |
$-0.03B |
$0.01B |
-156.25% |
| 2024-09-30 |
$-0.02B |
$0.01B |
-97.67% |
| 2024-06-30 |
$-0.03B |
$0.02B |
-111.11% |
| 2024-03-31 |
$-0.04B |
$0.02B |
-116.79% |
| 2023-12-31 |
$-0.04B |
$0.03B |
-90.70% |
| 2023-09-30 |
$-0.03B |
$0.04B |
-68.00% |
| 2023-06-30 |
$-0.03B |
$0.05B |
-54.32% |
| 2023-03-31 |
$-0.03B |
$0.06B |
-52.99% |
| 2022-12-31 |
$-0.05B |
$0.06B |
-79.65% |
| 2022-09-30 |
$-0.06B |
$0.08B |
-99.13% |
| 2022-06-30 |
$-0.06B |
$0.04B |
-112.92% |
| 2022-03-31 |
$-0.06B |
$0.05B |
-108.94% |
| 2021-12-31 |
$-0.06B |
$0.06B |
-92.42% |
| 2021-09-30 |
$-0.07B |
$0.06B |
-97.56% |
| 2021-06-30 |
$-0.08B |
$0.07B |
-100.31% |
| 2021-03-31 |
$-0.08B |
$0.08B |
-89.01% |
| 2020-12-31 |
$-0.10B |
$0.08B |
-95.48% |
| 2020-09-30 |
$-0.09B |
$0.10B |
-85.32% |
| 2020-06-30 |
$-0.09B |
$0.11B |
-76.82% |
| 2020-03-31 |
$-0.09B |
$0.11B |
-78.63% |
| 2019-12-31 |
$-0.08B |
$0.12B |
-65.10% |
| 2019-09-30 |
$-0.09B |
$0.12B |
-63.27% |
| 2019-06-30 |
$-0.08B |
$0.13B |
-53.98% |
| 2019-03-31 |
$-0.08B |
$0.15B |
-46.27% |
| 2018-12-31 |
$-0.08B |
$0.16B |
-45.65% |
| 2018-09-30 |
$-0.07B |
$0.18B |
-44.97% |
| 2018-06-30 |
$-0.06B |
$0.20B |
-58.65% |
| 2018-03-31 |
$-0.05B |
$0.13B |
-94.12% |
| 2017-12-31 |
$-0.05B |
$0.09B |
-197.80% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.002B |
$0.000B |
|
UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States.
|
